Atavistik Bio

Atavistik Bio is a private, pre-clinical stage biotech founded in 2021 and based in Cambridge, Massachusetts. The company's core innovation is the Atavistik Metabolite-Proprietary Screening (AMPS) platform, integrated with AI, which is designed to unlock cryptic allosteric binding sites to develop transformative therapeutics. Led by an experienced team with a strong track record in drug discovery, the company is building an internal pipeline in oncology and rare diseases while seeking partnerships to expand into other therapeutic areas.

Atavistik Metabolite-Proprietary Screening (AMPS) platform integrated with a proprietary AI-enabled discovery engine. It combines computational and experimental techniques to identify cryptic allosteric binding pockets on proteins by studying natural metabolite-protein interactions.

Competition is intense in the allosteric drug discovery space, with companies like Relay Therapeutics, Nimbus Therapeutics, and Black Diamond Therapeutics also using advanced computational and structural biology approaches. Large pharmaceutical companies are also heavily investing in internal and partnered allosteric programs. Atavistik differentiates by focusing on metabolite-inspired interactions and its integrated AMPS platform.